C. difficile colitis

Recurrent Clostridioides difficile infection (CDI) in older adults presents a significant clinical challenge, often complicated by comorbidities and polypharmacy. Treatment necessitates a balance between effectively eradicating C. difficile and minimizing further disruption of the gut microbiome. For initial recurrences, fidaxomicin is often preferred due to its narrow spectrum and lower recurrence rates compared to vancomycin. For multiple recurrences, fecal microbiota transplantation (FMT) has emerged as a highly effective therapy, restoring microbial diversity and reducing the risk of further episodes. Bezlotoxumab, a monoclonal antibody targeting C. difficile toxin B, can be considered as adjunctive therapy to standard antibiotics like vancomycin to reduce recurrence risk. Antibiotic stewardship is crucial; avoiding unnecessary antibiotic use is paramount in preventing future CDI. Explore how integrating FMT and bezlotoxumab into your treatment algorithms can improve outcomes in recurrent CDI cases. Consider implementing a standardized CDI management protocol that incorporates antibiotic stewardship principles and emphasizes patient education on infection prevention measures. Learn more about optimizing long-term management strategies for recurrent CDI.

Differentiating Clostridioides difficile infection (CDI, also known as C. diff colitis) from other causes of acute diarrhea requires careful clinical evaluation and targeted diagnostic testing. Consider a CDI diagnosis in hospitalized patients, particularly those with recent antibiotic exposure, presenting with watery diarrhea, abdominal pain, and possibly fever or leukocytosis. Distinguishing CDI from other infectious or inflammatory causes, like infectious colitis or inflammatory bowel disease flare, can be challenging. Initial evaluation should include a detailed patient history focusing on antibiotic use, recent hospitalization, and presence of CDI risk factors. The most sensitive initial diagnostic test is a nucleic acid amplification test (NAAT) for C. difficile toxin genes in stool. Enzyme immunoassays (EIAs) for C. difficile toxins A and B can be used but are less sensitive. A positive NAAT result, coupled with clinical findings, usually confirms the diagnosis. If NAAT is negative but clinical suspicion remains high, consider repeat testing or sigmoidoscopy to visualize pseudomembranes, a characteristic finding in pseudomembranous colitis, a severe form of CDI. Learn more about interpreting CDI diagnostic tests and developing an effective diagnostic algorithm for acute diarrhea.

Preventing the spread of Clostridioides difficile infection (CDI) in healthcare settings requires a multi-pronged approach emphasizing infection prevention and control. Hand hygiene remains the cornerstone of CDI prevention, with healthcare providers needing to adhere to meticulous handwashing with soap and water or using an alcohol-based hand rub, especially after contact with CDI patients or their environment. Contact precautions, including the use of gloves and gowns, are essential when caring for patients with confirmed or suspected CDI. Environmental cleaning and disinfection are critical. Surfaces in patient rooms and common areas should be cleaned regularly with EPA-registered sporicidal disinfectants. Effective cleaning involves mechanical removal of C. difficile spores followed by disinfection. Appropriate antibiotic stewardship practices are vital in minimizing the selective pressure that promotes C. difficile overgrowth. Explore how implementing an antimicrobial stewardship program can reduce CDI incidence. Consider implementing regular surveillance programs to track CDI rates and identify outbreaks promptly. Learn more about integrating evidence-based guidelines into your facility's infection control protocols.